<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[아라온테크 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=12805></link><description><![CDATA[아라온테크 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 05 May 2026 08:20:41 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2010/08/2039103817_20100830171006_1392200924.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial for AAD-2004 , a Potent Spin Trapping Molecule and Microsomal Prostaglandin E Synthase-1 Inhibitor, Targeting Alzheimer‘s, Parkinson’s and Lou Gehrig&#039;s Disease]]></title><link>https://www.newswire.co.kr/newsRead.php?no=494044</link><description><![CDATA[수원--(뉴스와이어)--Neurotech Pharmaceuticals Co., Ltd. has begun dosing in the Phase 1 clinical testing of AAD-2004.   AAD-2004 was developed as a dual function drug to remove free radicals and PGE2, the key mediators of nerve injury in Alzheimer‘s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).  The Phase 1 clinical trial was init...]]></description><pubDate>Tue, 31 Aug 2010 11:58:23 +0900</pubDate></item><item><title><![CDATA[뉴로테크, 알츠하이머 · 파킨슨 · 루게릭 질환 치료신약후보 AAD-2004 임상개발 순조롭게 진행 중]]></title><link>https://www.newswire.co.kr/newsRead.php?no=494039</link><description><![CDATA[수원--(뉴스와이어)--코스닥시장 상장기업 ㈜뉴로테크는 자회사인 뉴로테크  에서 진행중인 신약후보물질 AAD-2004 임상 1상이 순조롭게 진행되고 있다고 발표했다.   AAD-2004는 알츠하이머성 치매, 파킨슨병, 루게릭병에서 신경 손상을 유발하는 주요한 뇌독성 매개체인 프리라디칼과 프로스타글란딘 E2를 제거하는 복합 약리작용을 갖는 약물로 개발되어 왔으며, 지난 4월에 건강한 성인 지원...]]></description><pubDate>Tue, 31 Aug 2010 11:57:40 +0900</pubDate></item></channel></rss>